Destiny Pharma Holdings plc (DEST) Ord GBP0.01

- Add to watchlist
- Create an alert
- This stock can be held in a




Business summary
Destiny Pharma plc is a clinical stage, biotechnology company. The Company is engaged in the discovery, development, and commercialization of novel medicines with a focus on infection prevention. It is focused on developing novel antimicrobial drug from its exeporfinium chloride platform and also from two biotherapeutic products. Its pipeline includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. XF-73 nasal gel is developed for the prevention of post-surgical staphylococcal infections. NTCD-M3, which is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. NTCD-M3 is used for the prevention of C. difficile infection (CDI) recurrence. XF-73 derma is developed for the prevention and treatment of serious infections associated with wounds and ulcers such as diabetic foot ulcers (DFUs). The Company is co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.
Contact details
Important dates
General stock information
- EPIC:
- DEST
- ISIN:
- GB00BDHSP575
- Market cap:
- £29.32 million
- Shares in issue:
- 73.31 million
- Sector:
- Pharmaceuticals & Biotechnology
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.